問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間:2023-09-19

莊名凱
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

30Cases

2019-10-30 - 2027-10-27

Phase III

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX
  • Condition/Disease

    Acquired hemophilia

  • Test Drug

    Fitusiran

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting3Sites

Terminated3Sites

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
  • Condition/Disease

    Hemophilia A or B

  • Test Drug

    Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2023-05-09 - 2026-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-05-01 - 2039-02-01

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2021-08-01 - 2027-10-27

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-05-15 - 2021-06-11

Phase II

Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors
  • Condition/Disease

    hemophilia A or B

  • Test Drug

    BAY 1093884

Participate Sites
6Sites

Terminated5Sites

2023-10-01 - 2028-10-07

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3